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Abstract
Background: Human blood coagulation factor VIII (fVIII) is a large plasma glycoprotein with sequential domain
arrangement in the order A1-a1-A2-a2-B-a3-A3-C1-C2. The A1, A2 and A3 domains are interconnected by long
linker peptides (a1, a2 and a3) that possess the activation sites. Proteolysis of fVIII zymogen by thrombin or factor
Xa results in the generation of the activated form (fVIIIa) which serves as a critical co-factor for factor IXa (fIXa)
enzyme in the intrinsic coagulation pathway.
Results: In our efforts to elucidate the structural differences between fVIII and fVIIIa, we developed the solution
structural models of both forms, starting from an incomplete 3.7 Å X-ray crystal structure of fVIII zymogen, using
explicit solvent MD simulations. The full assembly of B-domainless single-chain fVIII was built between the A1-A2
(Ala1-Arg740) and A3-C1-C2 (Ser1669-Tyr2332) domains. The structural dynamics of fVIII and fVIIIa, simulated for
over 70 ns of time scale, enabled us to evaluate the integral motions of the multi-domain assembly of the co-
factor and the possible coordination pattern of the functionally important calcium and copper ion binding in the
protein.
Conclusions: MD simulations predicted that the acidic linker peptide (a1) between the A1 and A2 domains is
largely flexible and appears to mask the exposure of putative fIXa enzyme binding loop (Tyr555-Asp569) region in
the A2 domain. The simulation of fVIIIa, generated from the zymogen structure, predicted that the linker peptide
(a1) undergoes significant conformational reorganization upon activation by relocating completely to the A1-
domain. The conformational transition led to the exposure of the Tyr555-Asp569 loop and the surrounding region
in the A2 domain. While the proposed linker peptide conformation is predictive in nature and warrants further
experimental validation, the observed conformational differences between the zymogen and activated forms may
explain and support the large body of experimental data that implicated the critical importance of the cleavage of
the peptide bond between the Arg372 and Ser373 residues for the full co-factor activity of fVIII.
Background
The Human blood coagulation factor VIII (fVIII) is an
essential protein involved in the intrinsic coagulation
pathway. Factor VIII is synthesized as an ~300 kDa sin-
gle chain protein containing 2332 residues and com-
posed of six domains: A1-a1-A2-a2-B-a3-A3-C1-C2 [1].
The A-domains are interconnected by short linker
peptides that are rich in clusters of acidic residues. The
linker peptides correspond to the residues: 337-372 (a1)
between A1 and A2 domains; 711-740 (a2) at the C-ter-
minus of A2-domain and 1649-1689 (a3) between B and
A3 domains. Activation of fVIII by thrombin or factor
Xa (fXa) at three proteolytic sites Arg372-Ser373 (A1-
A2 junction), Arg740-Ser741 (A2-B junction), and
Arg1689-Ser1690 (B-A3 junction) yields functionally
active factor VIII (fVIIIa) that circulates in blood as a
hetero-trimer among the heavy chain domains A1, A2
and the contiguous light-chain domains A3-C1-C2.
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enzyme factor IXa (fIXa) in the intrinsic pathway of
blood coagulation cascade during the proteolytic activa-
tion of zymogen factor X (fX). The catalytic activity of
fIXa itself is very poor in the proteolysis of fX, but
increases dramatically when bound to the co-factor
fVIIIa [2]. The role of fVIIIa is to increase the catalytic
rate constant (Kcat) of fX activation by several orders
(10
6 fold) of magnitude and also to reduce the Kd for its
interaction with fIXa and the Km for substrate fX [3,4].
The clinical significance of fVIIIa is manifested by func-
tional defects triggered by genetic mutations or acquired
inhibitors that result in Hemophilia-A, a severe bleeding
hereditary coagulation disorder affecting 1 in 5000 peo-
ple [2]. The domain and sequence details of the models
studied in the current work are shown in Figure 1.
The circulating fVIIIa in blood plasma has limited
half-life due to rapid dissociation of A2 domain [5]. The
loss of A2 domain has been attributed to the weak
A2-subunit interactions with A1 and A3 domains [6].
Consequently, a number of experimental site-specific
mutagenesis studies have been directed towards under-
s t a n d i n gt h es p e c i f i cr e s i d u e si n v o l v e di nt h ei n t e r -
domain interactions as well as its interactions with the
enzyme fIXa and substrate fX [7-12]. Despite a great
progress in such efforts, the atomic level details of the
full structures of zymogenic and activated forms of fVIII
still remain unclear. The detailed three-dimensional
structures of fVIII and fVIIIa are essential pre-requisites
not only to understand the structural features but also
the interactions with its physiological activators (throm-
bin and fXa) and proteins associated with the intrinsinc
tenase pathway (fIXa and fX). Recently two low-resolu-
tion (2R7E:3.7 Å and 3CDZ:3.98 Å) X-ray crystal struc-
tures of fVIII zymogen were reported [13,14]. Both
models were derived by fitting the electron density
space of fVIII crystals with the homology models of the
individual domains derived from the human ceruloplas-
min, bovine factor Va (fVa) crystal structure and a high-
resolution X-ray crystal structure of C2 domain.
The A-domains of fVIII are homologous to the copper-
binding ceruloplasmin protein with ~35% sequence
identity while the C-domains belong to discoidin family
of proteins with variable homology. Both crystal struc-
ture models reported unusually high degree of thermal
disorder with the average thermal B-factors of over 195
Å
2. While these models provided a great detail about
the overall global features of the domain organization
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Figure 1 The schematic representation of the sequence and domain arrangement of A) the full model of zymogen fVIII; B) the B-
domainless fVIII, used in the present study; C) the activated fVIII. The functionally important calcium and copper ions bound to the inter-
and intra-domains are also shown.
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tion of the crystal structures limits their reliability for
the atomic-level structural details of the domain-domain
interactions. Backbone superimposition of the two crys-
tal structures (PDB: 2R7E and 3CDZ) revealed signifi-
cant conformational differences in the solvent-exposed
loop regions. Also, the reported crystallographic data
lacks the structural information for the functionally
important linker peptides that interconnect the
A-domains. These regions include the acidic linker
peptide between Pro333 (A1-domain) and Lys377
(A2 domain); the C-terminal peptide from Lys713 to
Arg740 within the A2-domain.
In this paper, we developed the solvent-equilibrated
B-domainless solution structures of zymogen fVIII and
its activated form, fVIIIa, in several stages starting from
one of the X-ray crystal structures (PDB ID:2R7E) [13]
by refining the models using MD simulations in explicit
water. The development of the full solution structure of
fVIII zymogen followed the modeling and refinement of
two key regions: 1) Refinement of the core region of the
protein for which the crystal coordinates are available;
2) Prediction of the structures for two acidic rich linker
peptides interconnecting the A1:A2 and A2:A3 domains
for which the coordinates are not available. The solvent
equilibrated solution structures of fVIII and fVIIIa pre-
dicted that the active and zymogenic forms may have
significant conformational differences around the puta-
tive fIXa binding site in the A2 domain. While the pro-
posed structure of the linker peptide between the A1
and A2 domains is predictive in nature and requires
experimental validation, they corroborate well with the
existing hypothesis that the exposure of the putative
fIXa binding loop (Tyr555-Asp579) in the A2-domain is
critical for productive interactions with fIXa enzyme
during the intrinsic tenase (fVIIIa.fIXa) complex forma-
tion. A detailed account of the intra and inter-domain
interactions among the five domains and a correlation
with known biochemical mutagenesis data is presented.
Results
Human fVIII model in the current study was built using
the 3.7 Å resolution X-ray crystal structure of fVIII pub-
lished by Shen et al [13]. Another X-ray crystal structure
with 3.97 Å resolution using similar synthetic construct
and crystal form was published [14]. Both models were
built based on fitting the homology models of fVIII into
the electron density map of fVIII X-ray crystallographic
space (PDB ID: 2R7E and 3CDZ). The alignment of the
backbone atoms of the two structures revealed signifi-
cant conformational differences in several solvent-
exposed loop regions, though the core region of the
both structures was similar with an overall RMS differ-
ence of 0.98 Å for the backbone atoms. The fIXa
binding loop (Tyr555-Asp569) within the A2-domain
and the surrounding region was also markedly different
in both crystal structures. This region was implicated in
several experimental studies as functionally important
for fVIIIa:fIXa interactions as well as thrombin interac-
tions with fVIII during the activation. The A1-A2-A3
domains of fVIII share ~35% sequence identity with the
structure of human ceruloplasmin, from which the
X-ray structural models were built. It is not surprising
that such low sequence identity reflected on the poor
stereo-chemical quality of the crystal structures. The
analysis of the Ramachandran plot showed that the
initial X-crystal structure has ~290 residues (out of 1329
residues) as the outliers in the Phi-Psi dihedral space
(Additional file 1:Figure S1). In contrast, the MD equili-
brated fVIII zymogen structure, corresponding to 70 ns
of MD trajectory, showed marked improvement in the
stereochemical quality with only three non-glycine resi-
dues (out of 1404) as the outliers in the Ramachandran
plot. These residues are located in the solvent-exposed
loop regions and some residues appeared to vary from
one snapshot of MD trajectory to the other, perhaps
representing the conformational sub-states. The overall
structure of fVIII showed 99.7% of the residues in the
generously allowed region of the Ramachandran plot.
Similarly, the solution structure of fVIIIa showed 99.5%
of the residues in the most favorable region with only
four non-glycine residues in the outlier region. The eva-
luation of the “goodness of fit” of the model in compari-
son with the proteins in the crystal structure database
by ProSA server [15]https://prosa.services.came.sbg.ac.
at/prosa.php ranked the MD derived fVIII zymogen
model with a Z-score of -11.8 and that of the fVIIIa
structure with the corresponding score of -11.5. These
values were considerably less than the maximum accep-
table value of -0.3 when compared with the range of
native conformations of the PDB templates. The corre-
sponding Z-score of the X-ray structure was -7.4
(PDB = 2R7E). The domain-wise alignment of the start-
ing X-ray crystal structure with the MD derived model
showed overall agreement in the core-region of the
domains but significant differences in the domain-
domain interface in the A-domains. The superimposed
structures are shown in Additional file 2: Figure S2. The
structures of the fVIII zymogen and its activated forms,
corresponding to 75 and 80 ns of MD snapshots respec-
tively, are shown in Figures 2 and 3 with highlighting
the important regions in the proteins.
In order to understand the overall dynamics of the
structures, we monitored the structural changes over
the simulation time by computing the RMS deviations
with reference to the starting structure (Figures 4a-b).
The RMS deviations of fVIII were much larger when we
considered all the five domains, but relatively stable
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Page 3 of 20when plotted the A1-A1-A3-C1 domains combined
excluding the C2 domain. This difference can be attrib-
uted to the flexibility of the C2-domain than the other
four domains. Despite the large binding surface between
the C2 and the adjacent C1 domain, the two domains
do not have energetically significant inter-domain inter-
actions between them (vide infra). We have generated
10 possible models of fVIII and fVIIIa by clustering the
last 10 ns of the MD trajectory. The backbone superim-
posed structures of the 10 models for both forms are
presented in Figure 5. It is evident from the figure that
while the A1-A2-A3-C1 domains appeared relatively
stable, the C2-domain showed significant flexibility in
both the structures. Also, it is evident from the figure
that the A2-A3 peptide linker region showed some
degree of flexibility in the zymogenic form. The C-ter-
minus of the A2-domain in the activated form that is
mostly occupied by negatively charged residues also
showed large flexibility.
To probe the intra and inter-domain mobility of the
solvent-exposed loop regions further, we computed the
atomic positional fluctuations in fVIII and fVIIIa mod-
els. A comparative plot of the positional fluctuations
averaged over the last 2 ns of MD trajectory is shown
for the A1-A2 and A3-C1-C2 domains in Figures 6a,b.
Atomic positional fluctuations are often used to charac-
terize the domain flexibility in multi-domain protein
systems as well as to understand the hyper-variability of
the solvent exposed loop regions. Typically, the loops
that have positional fluctuations more than 50 Å
2 may
be considered hyper-variable in the protein structures.
In experimental X-ray crystal structures, the B-factors
usually provide such information. While it is difficult to
quantitatively relate the positional fluctuations from MD
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Figure 2 The solution structural model of human B-domainless fVIII zymogen derived from the MD snapshot that corresponds to 75 ns
of MD simulation trajectory. The coordinating calcium (red spheres) and copper (pink spheres) ions, tyrosine sulfation sites (ball-and-stick) are
highlighted. The A1-A2 acidic linker may be seen blocking the putative fIXa binding Y555-D569 loop (magenta color) in the A2-domain
(orange color). The solvent-exposed proteolytic site (Arg372-Ser373) is also shown. The platelet surface shown in the figure is merely a schematic
representation and not modeled in the current study.
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X-ray crystal structures, both share a qualitative com-
parison. Since the published X-ray crystal structure of
fVIII was derived by fitting the homology models, the
crystallographic B-factors were assigned >190 Å
2 of
positional uncertainty. Consequently we could not make
direct comparison with the computed atomic positional
fluctuations. It is evident from Figures 6a,b that the
overall flexibility of the solvent-exposed loop regions is
very similar in both zymogen and activated forms. In
line with the RMSD plot (Figure 4a), the conformational
flexibility of the C2 domain (from Cys2021 to Cys2326)
is clearly evident in both fVIII and fVIIIa with more
than 125 Å
2 of the atomic positionalf l u c t u a t i o n s .T h e
acidic linker peptide region between the A1 and A2
domains spanning the residues Pro330 and Lys380, the
Tyr sulfation sites at 
the end of A2-domain
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Figure 3 The solution structure of activated fVIII derived from the MD snapshot that corresponds to 80 ns of MD simulation
trajectory. The conformational reorganization of the A1-A2 acidic linker peptide (orange color), upon the cleavage of the Arg372-Ser373 bond,
may be seen from the MD simulations. The exposed fIXa binding loop in the A2-domain is highlighted (magenta color).
Figure 4 The RMS deviations of the backbone atoms of A) the zymogen (left) and B) the activated form (right) of factor VIII as
compared to the starting structure.
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1805 and 1889-1901 exhibited relatively large mobility
during the MD simulations.
Discussion
Structure and conformation of A1/A2 and
A2/A3 linker peptides
In the present study, the acidic-rich linker peptide con-
necting the residues Cys329 of A1-domain and Thr381
of A2-domain was derived based on MD simulations for
a total time of 200 ns. Though the starting structure for
the loop optimization was based on a linear conforma-
tion, over the MD refinement, the linker peptide adopted
helical structure for two acidic rich regions. The helices
correspond to the sequence EDY
sulfDDDLTD from
Glu344 to Asp352 and the activation peptide sequence
SFIQIR from Ser367 to Arg372 as shown in Figure 7.
The linker peptide conformation was stabilized, as may
Figure 5 Backbone superimposed structures of A) zymogenic (left) and B) activated (right) forms of factor VIII, representing the top
ten clusters of the MD trajectory. The last 10 ns of the simulation data (70-80 ns) was used for clustering.
Figure 6 Atomic positional fluctuations in A1-A2 and A3-C1-C2 domains of A) active and B) zymogenic forms of fVIII.T h ed a t a
corresponds to 2 ns of MD simulation data extracted from 75 to 77 ns.
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interactions with the A1 and A2 domains. These corre-
spond to interactions of Glu332:Asp302; Arg336:Asp302/
Glu331 and Arg359:Asp459. The two helices are con-
nected to the A1 and A2 domains by largely flexible
structure with no specific secondary structure. The pre-
dicted helical structure for Glu344-Asp352 may have a
functional significance as this region was implicated to
have a potential role in recognizing the substrate fX by
the tenase complex (fVIIIa.fIXa). In order to verify that
the helical preference for the two proposed regions
between A1 and A2 domains is reproducible, we carried
out two independent MD simulations on the peptides
correspond to the residues Arg336-Met355 and Val359-
Thr380 for 50 ns (data not shown). Both structures con-
verged over the simulation period to helical conformation
(Figures 7c,d). The reproducibility of the helical nature of
the two proposed regions assures the reproducibility of
the structure prediction for the two acidic patches.
The linker peptide connecting Cys710 (A2-domain) and
Thr1695 (A3-domain) in the B-domainless fVIII form
was modeled based on a truncated model between the
A2 and A3 domains as described in the modeling section.
The residues at the C-terminus end of A2 domain are
predominantly acidic with three tyrosine residues at posi-
tions 718, 719 and 723 that were post-translationally sul-
fated. In addition, the residue 1680 at the junction of
A2-A3 domain is also sulfated. The A2-A3 linker peptide
was stabilized over the 100 ns of MD simulations as
shown in the RMSD plot (Figure 8c). The last 20 ns of
the MD trajectories were clustered into 10 conformations
and are shown in Figure 8b. It is evident from the figure
that the optimized loop structure shows significant flex-
ibility with the acidic patch of residues at the C-terminus
of the A2-domain form a stable hairpin-like structure
with the sulfated tyrosines projecting out to the surface.
Structural features of metal ions in factor VIII/VIIIa
The function and stability of the fVIII depend critically
on metal ions, particularly calcium and copper ions, cova-
lently bound to the protein. Studies based on the recon-
stitution of isolated subunits as well as site-specific
mutagenesis studies indicated that Type-I (Cu
+)a n d
Type-II (Cu
+2) ions covalently bind to factor VIII. These
Figure 7 Models used for generation of linker peptide between A1 and A2 domains, A) The A1 and A2 domains with missing linker
peptide and the distance between the core residues Glu332 (A1 domain) and Pro379 (A2 domain) is shown. B) The top ten structures of the
proposed linker peptide derived from clustering the last 30 ns of 100 ns MD trajectory are presented. Converged structures of isolated
sequences C) Arg336-Met355 and D) Asn369-Lys380 in the linker peptide (based on 50 ns of MD simulations each) to demonstrate the
reproducibility of the helical nature of the sequences is shown. E) The RMS deviations in the backbone (Ca) atoms during the simulations of the
linker peptide model with reference to the starting structure are shown.
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+)
was to enhance the inter-chain affinity by ~100 fold [16].
It was also showed that the Type-I copper (Cu
+1) bound
to the inter-domain interface is not sufficient alone to
regenerate the full co-factor activity but might need a cal-
cium ion binding to augment the stability of the struc-
ture. However, the precise location of the calcium ion
binding, probably a low-affinity binding site as suggested
by Wakabayashi et al, is not yet experimentally character-
ized [17]. It is also interesting that the calcium ion, itself,
has little effect on inter-subunit affinity yet converts the
inactive dimer to an active form [18]. While high (mM)
concentrations of Cu(II) fail to support fVIII reconstitu-
tion, low (μM) levels of Cu(I) or Cu(II) stimulate recon-
stitution in the presence of calcium or manganese ions
[19]. Activity generation due to calcium ion binding to
fVIII was shown to be a slow process and thus a slow
conformational transition may be involved [20]. Results
from Factor Xa generation experiments suggested that
fVIII might possess two calcium-binding sites with differ-
ing binding affinities. A high affinity calcium ion was
proposed to bind to A1-domain with Kd value of 8.9-18.9
μM while a low-affinity site was proposed to bind to an
unknown site with a weak Kd value of 4.0 mM [21].
Calcium-ion coordination
Several early mutagenesis studies have suggested that the
A1-domain region spanning residues 110-126 constitute a
calcium-ion binding site [22]. The loop has eight acidic
residues (E110, E113, D115, D116, E122, E124, D125 and
D126) providing an ideal site for calcium coordination. In
the starting X-ray crystal structure, one calcium ion was
located in the A1 domain with coordination to the side-
chain oxygen atom of Asp126 and the backbone oxygen
atom of Ala112. No other coordinating oxygen atoms
were located within the 5 Å vicinity of the calcium atom.
The calcium ion has been well characterized in several
blood coagulation proteins to bind to three to four amino
Figure 8 The structural convergence of the A2-A3 linker peptide generated using a reduced model between A2 and A3 domains. A)
The starting conformation, B) the converged structures (based on clustering the last 30 ns of MD trajectory) of the linker peptide and C) the
corresponding backbone (Ca atoms) RMS deviations with reference to the starting conformation are shown.
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[23,24]. Experimental alanine mutagenesis studies demon-
strated that the mutation of Glu110, Asp116, Glu122,
Asp125 or Asp126 led to significant reduction (or lost) in
Ca
2+ binding affinity [25,26]. In contrast, the Ala-substitu-
tion at Glu113, Asp115 or Glu124 showed wild-type-like
activity with little or no reduction in calcium ion affinity.
To be consistent with the experimental data, we placed a
calcium ion in the A1-domain loop with initial coordina-
tion optimally close to the side-chain carboxylate groups
of all possible negatively charged residues (Glu110,
Glu113, Asp125 and Asp126). Over the course of molecu-
lar dynamics simulation, the calcium ion developed a
stable octahedral co-ordination network with the side-
chain carboxylate group atoms OD1 and OD2 of Asp126,
OE1, OE2 atoms of Glu110 and OD1 of Asp125. Three
oxygen atoms from the solvent water were also involved
in completing the coordination network (Figure 9a). The
coordination network of calcium ion in the A1-domain is
identical in both active and zymogenic forms of fVIII.
As mentioned previously, it was proposed in biochem-
ical studies that fVIII might also have a second low-affinity
calcium ion bound to the A-domains that contribute
to the inter-domain affinity. While there was no structural
data so far to characterize such interaction, the current
MD simulations predicted, for the first time, a stable cal-
cium ion binding to the interface of A2 and A3 domains.
The simulation setup of fVIII and fVIIIa contained several
calcium ions in the water solvent that were not bound to
the protein. Within the initial 20 ns of the simulation per-
iod, one of the calcium ions from the solvent emerged to
appear close to Glu604 of A2-domain and Glu1908 of A3-
domain residues and developed a stable octahedral coordi-
nation network with the side-chain oxygen atoms (OE1
and OE2) of the carboxylate groups together with four
oxygen atoms of the solvent water molecules (Figure 9b).
While the structural and functional relevance of the sec-
ond calcium ion is not known, the simulations suggest
that this might be considered as the second low-affinity
calcium-ion binding to the fVIII protein that involves A2
and A3 domains with Glu604 and Glu1908 residues. Per-
haps mutation of either or both residues by experimental
mutagenesis studies might further clarify the role of the
second calcium ion in the proposed site.
Figure 9 The octahedral calcium coordination network in A) A1-domain; B) at the interface of A2 and A3 domains and C) the distance
plot of a solvent calcium ion coordination with one the side-chain carboxylate atoms are shown.
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Factor VIII is structurally homologous to the copper-
binding human ceruloplasmin and factor Va [27,28].
The comparison of the three structures, together with
the biophysical and experimental mutagenesis data
[29,30], suggests that two Type-I (Cu
+1) copper ions
bind to the A1 and A3 domains. The reconstitution of
fVIII from isolated heavy and light chains revealed a pri-
mary role for copper ion was to enhance the inter-chain
affinity by ~100 fold [31]. It is known, in many copper
binding proteins, that the copper ion coordinates with a
network of residues comprising His/Cys/Met or with
His/His/His network [32-34]. In factor VIII, two such
ideal sites exist within the A1 and A3 domains. These
sites are: His267/Cys310/His315/Met320 in A1-domain
and His1954/Cys2000/Met2010/His2005 in A3-domain.
Also, a His99/His161/His1957 network was found
between A1 and A3 domains. The site-specific mutagen-
esis studies have indicated that the Cys310Ser mutation
in the A1-domain showed marked reduction in the spe-
cific activity of fVIIIa. In contrast, the A3-domain muta-
tions Cys2000Ser and His1957Ala did not affect factor
VIII specific activity where as the A1-domain mutation
His99Ala yielded ~75% reduction compared to the wild-
type. While some of these studies provided a conflicting
view of the role of copper ion co-ordination, it is note-
worthy that the mutagenesis studies were based on sin-
gle-point mutations. Within the A1 and A3 domains,
the copper is coordinated with two nitrogen atoms of
Histidines and side-chain sulfur atoms of Cys and Met
residues. It is possible that the binding affinity might
not be altered to noticeable effect by mutating single-
residue, while the other three residues could be suffi-
cient to hold the copper-coordination network. The
coordination network of the copper ions with the MD
derived model is shown in Figures 10a-c. The ions
maintained a stable coordination network during the
simulation period. The histidine ring nitrogen atoms of
Figure 10 The tetrahedral copper ion coordination network in A) the A1 domain, B) the A3 domain and C) at the interface of A1 and
A3 domains are shown.
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domain are coordinated with copper ion with the bond
distance of ~2.1 Å. The copper ions within the A1 and
A3 domains coordinated with the side-chain sulfur
atoms of Cys and Met residues with the coordination
distance of 2.1 Å while the histidine nitrogen atoms are
at 2.2 Å distance.
Post-translational modification sites
The B-domainless FVIII contains five ASN-glycosylation
(N-linked) sites. These sites are located in A1 (41 and
239), A2 (582) and A3 (1810) and C1 (2118) domains
[35]. All the five sites were modified to N-GlnAc linked
carbohydrate attachments. The solution-structure
showed that except for Asn2118, all the modified aspar-
agines residues are solvent exposed. The Asn2118 resi-
due is somewhat buried in the deep cleft between the
A3 and C1 domains.
There are six tyrosine sulfation sites in FVIII. These are
located at the positions: 346 (A1 domain), 1664, 1680
(A3 domain) and at 718,719 and 723 in the C-terminus
end of the A2 domain [36,37]. Except for Tyr1664 which
is not present in our model (The N-terminus of A3
domain begins from Ser1669 in our fVIII model), rest of
the tyrosine residues were present in surface-loop regions
with complete exposure of the side-chains to the solvent.
The negatively charged sulfated tyrosines were implicated
to have direct influence on the thrombin activation rates
of fVIII. For instance, the mutation Tyr346Phe, located
within the A1-A2 acidic linker peptide, accelerated the
r a t eo ff V I I Ic l e a v a g eb yt h r o m b i n[ 3 8 ] .I nc o n t r a s t ,t h e
mutation of Tyr346Cys results in CRM
+ hemophilia A
[39]. This defect was characterized by a discrepancy in
one-state and two-stage clotting assays and the patholo-
gical implications were due to reduced activation rates.
In the model of fVIII zymogen, the Tyr346
sulf is located
within the a-helix formed by the acidic-rich sequence
EDY
sulfDDDLTD (from Glu344 to Asp352). One direct
impact of Tyr346
suf mutation to cysteine could be
the reduction of overall acidic nature of the helix and
possibly destabilizing the helix. It may also be seen from
Figures 2 and 3 that the sulfated tyrosine residues at
719,719 and 723 together with aspartic acid residues at
712, 717, 720, 721 and 724 generate a high density of
acidic cluster with the hairpin-like loop at the C-terminus
of A2-domain. This region was shown in experimental
studies as a likely thrombin exosite binding region during
the proteolysis of Arg372-Ser373 and/or Arg740-Ser741
peptide bonds [10,40]
Inter-domain interactions in fVIII/fVIIIa
The structural stability originating from the inter-domain
interactions of fVIII/fVIIIa is mainly due to the metal ion
dependent association and the inter-chain association
due to residue-level interactions. Indeed, 80% of the ther-
modynamic stability of fVIII is attributed to the latter.
Upon the generation of the fVIIIa followed by the clea-
vages at three proteolytic sites in B-domainless fVIII, the
activated form has limited half-life since it goes through
the spontaneous inactivation through A2 subunit disso-
ciation from the other domains [41]. While the specific
structural rationale is not clear, the interactions between
A2 and other domains were believed to be weak and lim-
ited [42,43]. An accurate account of atomic level interac-
tions is critical to understand the origins of stability as
well as to provide a structural correlation to the known
genetic or synthetic mutation data. The detailed interac-
tion data among the A-domains of fVIII/fVIIIa is tabu-
lated in Table 1 based on the equilibrated structures
derived from the MD simulation data. In order to esti-
mate the binding surface between fVIII domains, we
computed the solvent-accessible surface area (SASA)
using NACCESS program [44] with a probe radius of 1.4
Å. We estimated that the total surface area of fVIII and
fVIIIa are 69543 and 69106 Å
2 respectively. The buried
surface area among the A-domains (fVIII/fVIIIa) is as fol-
lows: A1:A2 (4022/3354 Å
2); A2:A3 (4329/3690 Å
2)a n d
A1:A3 (2709/2632 Å
2).
A1-A2 binding surface
Analysis of the interaction data showed significant con-
tribution form several ion-pair interactions that promote
stability between A1 and A2 domains as shown in Table
1. Some key interactions include the ion-pairs: Arg282:
Asp525; Arg484:Glu272; Arg490:Glu341; Lys493:
Asp318/Glu321 and Lys512:Glu354. Apart from these
major contributions, several hydrogen bond interactions
were identified at the binding surface between A1 and
A2 domains. It is worth-mentioning that the interaction
data from present MD models correlate well with the
published experimental mutagenesis data. In a recently
study on the characterization of A-domain residues that
contribute to the fVIII/fVIIIa stability, Wakabayashi and
Fay investigated a panel of mutations that contribute to
the A2-domain affinity with A1 and A3 domains [6].
They concluded from the study that the decay of fVIII
stability depends on the specific residues in the decreas-
ing order of: Arg282 > Ser524 > Asn684 > Arg531 >
Ser650 > Glu1829 > Tyr664 > His281. These mutations
showed marked decrease in the protein stability relative
to the wild-type fVIII in a one-stage clotting assay and
two-stage chromogenic factor Xa generation assay. The
design of these experiments was based on a homology
model of A1-A2-A3 domains derived from human ceru-
loplasmin template that shares ~35% sequence identity
with fVIII. Comparison of our MD model with the
homology model showed significant differences in the
inter-domain surface and perhaps the effect of some of
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Page 11 of 20Table 1 Interdomain hydrogen bonding interactions and corresponding distances (in Å) among A1 (1-330),
A2 (381-740) and A3(1669-2019) domains of the zymogenic and activated forms of fVIII.
fVIII zymogen Activated fVIII
A1:A2 interactions
R240 (NH1) L491 (O) 3.1 R240 (NH1) L491 (O) 2.8
T275 (OG1) D519 (OD1) 2.9 T275 (OG1) T481 (OG1) 2.9
R282 (NH1) D525 (OD1) 3.2 R282 (NH1) D525(OD1) 2.7
R282 (NH1) D525 (OD2) 2.6 R282 (NH1) D525 (OD2) 3.1
R282 (NH2) D525 (OD1) 2.8 R282 (NH2) D525 (OD2) 2.9
R484 (NH1) E272 (OE2) 2.7 S285 (OG) F673 (O) 2.6
R484 (NH2) E272 (OE2) 3.2 D482 (N) H274 (ND1) 3.0
R484 (NH2) Q305 (O) 2.9 V483 (N) G273 (O) 2.8
R490 (NH1) E341 (OE1) 2.8 R484 (NH1) E272 (O) 2.9
R490 (NH1) E341 (OE2) 3.3 R484 (NH1) E272 (OE1) 2.8
R490 (NH2) E341 (OE2) 2.9 R489 (NE) E272 (OE2) 2.9
K493 (N) F38 (O) 2.9 R489 (NH2) E272 (OE2) 2.8
K493 (NZ) D318 (OD1) 2.8 K493 (N) F38 (O) 3.1
K493 (NZ) E321 (OE1) 2.7 K493 (NZ) D318 (OD1) 3.5
K493 (NZ) E321 (OE2) 3.3 K493 (NZ) D318 (OD2) 2.9
K512 (NZ) E354 (OE1) 2.8 K493 (NZ) E321 (OE2) 2.8
Q645 (N) S314 (OG) 3.3 S674 (OG) E287 (OE2) 2.7
Q645 (NE2) S313 (O) 3.5
S674 (OG) E287 (OE1) 2.6
A1:A3 interactions
R226 (NH1) D1909 (OD2) 3.0 R220 (NH1) E1914 (OE2) 2.8
R226 (NH2) D1909 (OD1) 2.9 R220 (NH2) E1914 (OE1) 2.8
R226 (NH2) D1909 (OD2) 2.9 R220 (NH2) E1914 (OE2) 3.3
R1719 (NH1) D221 (OD2) 2.9 R226 (NH1) D1909 (OD1) 2.9
R1719 (NH2) D221 (OD1) 2.8 R226 (NH1) D1909 (OD2) 3.2
R1997 (NH1) E113 (O) 2.9 R226 (NH2) D1909 (OD2) 2.7
R1997 (NH2) E113 (O) 2.9 T263 (OG1) E2004 (OE2) 2.7
K1972 (NZ) D150 (OD1) 2.9 R1719 (NH1) D221 (OD1) 3.1
K1972 (NZ) D150 (OD2) 2.9 R1719 (NH1) D221 (OD2) 2.7
N1977 (ND2) S289 (OG) 2.9 R1719 (NH2) D221 (OD1) 2.7
N1977 (ND2) P290 (O) 2.8 R1997 (NH1) E113 (O) 3.2
K1992 (NZ ) Y105 (O) 2.9 R1997 (NH2) E113 (O) 2.8
N1977 (ND2) P290 (O)
K1992 (NZ) Y105 (O) 2.8
A2:A3 interactions
Y664 (N) K1967 (O) 3.0 N414 (ND2) Q1906 (OE1) 2.9
T669 (OG1) P1980 (O) 3.1 Y664 (N) K1967 (O) 2.9
S695 (OG) D1842 (OD1) 2.9 S695 (OG) D1842 (OD1) 2.8
Y729 (N) E1794 (OE1) 2.8 S695 (OG) D1842 (OD2) 3.5
Y729 (OH) R1797 (O) 2.9 S732 (OG) E1794 (OE2) 2.7
N734 (ND2) E1793 (OE2) 2.7 K733 (NZ) D1795 (OD1) 2.7
N735 (ND2) D1795 (OD1) 2.8 R1803 (NH1) P739 (O) 2.8
E738 (N) E1671 (O) 3.0 R1803 (NH2) E738 (OE2) 2.9
R740 (NH1) E1811 (OE1) 2.8 R1803 (NH2) P739 (O) 2.9
R740 (NH2) E738 (OE1) 2.7 K1804 (NZ) E738 (OE1) 2.7
R740 (NH2) E738 (OE2) 3.4 K1833 (NZ) Y664 (O) 2.8
S1669 (N) E738 (O) 3.1 K1833 (NZ) D666 (OD1) 2.8
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indirect influence of some of the neighboring residues
than the specific mutations proposed in their experi-
mental work.
The mutations of Arg282, Ser524 and Arg531 were
shown to increase the fVIII decay by > 5-fold. As shown
in Table 1, the Arg282 is ion-paired with Asp525 and
t h eA r g 2 8 2 A l am u t a t i o nw o u l di m p a c tt h eb i n d i n g
interactions between A1 and A2 domains. While the
effect of Asp525 mutation was not studied, the neigh-
boring residue Ser524 is located in the same loop that
Asp525 resides. The Ser524Ala mutation was also
shown to significantly increase the fVIII decay. This
residue is solvent exposed in the model of fVIII and per-
haps alanine mutation would effect the loop conforma-
tion that might, in turn, alter the conformation of
Asp525 and consequently the ion-pair interaction with
Arg282. It is also worth mentioning the ion-pair interac-
tion between Arg531 and Asp519. The Arg531Ala muta-
tion was shown to affect the inter-domain affinity.
While this residue is not involved in the inter-domain
interactions, it forms ion-pair with Asp519 which is
located in the same loop segment that Arg525 is
located. Thus, the Arg531 mutation would impair inter-
actions with Asp519 that might have structural conse-
quence in affecting the stability of Arg285:Asp525
interactions.
A1-A3 binding surface
Despite the relatively smaller binding surface compared
to that of A1:A2 domains, the A1 and A3 domains are
l a r g e l ys t a b i l i z e db yt h ec o pper ion coordination at the
A1 and A3 domain interface. In addition, four major
ion-pair interactions add to the overall binding affinity
between the two domains. These are Arg220:Glu1914;
Arg221:Arg1719; Arg226:Asp1909 and Glu113:Arg1997.
It should be noted that the Glu113 is located in the
calcium-binding loop within the A1 domain. The muta-
genesis studies suggested that the Glu113Ala mutation
within this calcium binding loop showed four-fold
increase in co-factor activity. While the mutation of
Glu113 to large polar residues was shown to be detri-
mental to the co-factor activity, Glu113Ala mutation
seems to increase the stability. In our structure, we
identify that the backbone oxygen atom of Glu113
forms hydrogen-bonding with two hydrogen atoms of
the side-chain of Arg1997 within the A3-domain. We
observed that this interaction was consistently main-
tained over the entire stabilized MD trajectory and,
indeed, was the only inter-domain interaction that con-
tribute to the association of the calcium binding loop to
the A3-domain. Therefore, the mutation of Glu113 into
other bulky groups might disrupt this interaction and
could be deleterious to the inter-domain affinity
between A1 and A3 domains.
A2-A3 binding surface
The interactions between the A2 and A3 domains in
fVIII zymogen are governed by a large number of
hydrogen bonded interactions. The A2:A3 surface has
three ion-pair interactions due to the clustered network
of charged residues Arg740:Glu378/Glu1811; Lys1833:
Asp666/Tyr664; Glu607:Arg1900/Ala1901. Unlike the
A1:A2 and A1:A3 domains that did not show a great
loss of inter-domain interactions upon activation, the
A2:A3 domain interface appears to loose a large number
of hydrogen bonds (9 out of 25) as seen from the Table
1. These differences reflected on the corresponding loss
of 640 Å
2 surface area in the activated form when com-
pared with that of the zymogen. The A2-subunit disso-
ciation in the activated form and the reduced half-life in
the blood plasma could be attributed, at least in part, to
the diminished interactions between the A2 and A3
domains. In a study based on the Glu1829Ala mutation,
Table 1 Interdomain hydrogen bonding interactions and corresponding distances (in Å) among A1 (1-330),
A2 (381-740) and A3(1669-2019) domains of the zymogenic and activated forms of fVIII. (Continued)
S1669 (OG) E738 (OE2) 2.7 N1904 (ND2) N414 (O) 2.9
V 1670 (N) P739 (O) 3.2 N1904 (ND2) N414 (OD1) 3.0
E 1671 (N) E738 (O) 3.1 Q1906 (N) P606 (O) 3.0
D 1795 (N) N734 (OD1) 3.1 K1967 (NZ) E665 (OE1) 2.9
R 1797 (NH1) L687 (O) 3.0
T 1826 (N) Y664 (OH) 3.1
K 1833 (NZ) Y664 (O) 2.9
K 1833 (NZ) D666 (OD1) 2.6
R 1900 (N) E607 (OE1) 2.7
A 1901 (N) E607 (OE1) 3.2
Q 1906 (N) P606 (O) 2.8
Q 1906 (NE2) E604 (OE1) 2.9
K 1967 (NZ) E665 (OE1) 2.8
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bute to the A2 subunit retention [9]. In the zymogen
structure, we noticed that the residue was bonded to the
backbone oxygen atom of Arg1966 of A3-domain. A
s i m i l a ro b s e r v a t i o nc a nb es e e ni nt h er e p o r t e dX - r a y
crystal structure of fVIII [14]. However, Glu1829 is
located in the loop that has direct interactions with the
A2-domain interface. At the interface, Tyr664 of A2-
domain is observed to have hydrophobic interactions
with Phe1830 residue of A3-domain via π-π stacking.
Thus, the mutation of Glu1829 could be seen as the
neighbor-effect in reducing the A2:A3 domain interac-
tions. The Asp666Ala mutation was shown to increase
the fVIII decay rates [45]. As shown in Table 1, Asp666
residue is bonded to Lys1833 though ion-pair.
Interactions of C1-C2 domains with A1-A2-A3 domains
The platelet binding C-domains together share 16962 Å
2
of buried surface with the A1/A2/A3 domains. Despite
the large binding surface, the C-domains have limited
stabilizing interactions with the A-domains. We noticed
that only one clustered ion-pair formation of Glu1751
with Arg2116 and Tyr2105. Other H-bonding interac-
tions include Arg4:Tyr2332; Ala1866:Ser2119; Glu1754:
Gln2113; Arg2116:Thr2122 and Tyr2115:Pro2142. Inter-
estingly, the C1-domain shares 670 Å
2 of surface area
with C2-domain but no hydrophobic or electrostatic
interactions were found between the two domains. As
discussed in the early part of the text, the large-scale
domain motions, that we observed (from RMSD calcula-
tions) when all the domains are considered, stems for
the lack of stabilizing interactions between the C2 and
C1 domains. As the C1-C2 domains seem to bind to the
platelet surface together, the overall structure of fVIIIa
might adopt a stabilizing orientation, for functional
co-factor activity, on the anionic phospholipids surface
through the likely hydrophobic interactions with C1-C2
domain residues Phe2093, Leu2251, Leu2252 and
Met2199 residues. All these residues are projected
towards the possible membrane surface.
Structural differences between zymogenic and activated
forms
The B-domainless factor VIII zymogen has three proteo-
lytic sites at Arg372 (A1-A2 junction), Arg740 (A2-B
junction) and Arg1689 (at the N-terminus of A3) that
must be cleaved by the physiological activator, thrombin
[46,47]. While the precise order of the cleavages is not
well-known, the proteolysis of Arg372-Ser373 peptide
bond is believed to be penultimate step in the activation
process of the zymogen and is essential for full co-factor
activity of fVIIIa. Recent biochemical studies suggested
that the proteolysis at either Arg740 or Arg1689 facili-
tates subsequent bond cleavages during the thrombin
catalyzed activation [48]. The Arg372-Ser373 site is
located in the linker peptide that has several acidic resi-
dues between the A1 and A2 domains. While the struc-
tural rationale behind the essential pre-requisite of the
cleavage of Arg372-Ser373 peptide bond is not known,
it was hypothesized that the cleavage of the bond
exposes a cryptic functional factor IXa-interactive site in
the A2-domain [49]. The acidic linker peptide confor-
mation in the solvent-equilibrated zymogen model
adopts the conformation that blocks the Tyr555-Asp569
loop in the A2 domain (highlighted in Figure 2). The
Arg372-Ser373 cleavage site can be clearly seen to mask
the fIXa binding site in the zymogen model. In the fac-
tor X activating complex fIXa/fVIIIa, residues 555-569
of the A2 domain are thought to bind to the protease
domain of factor IXa [50]. In another study, it was also
proposed that helix 330-338 of fIXa interacts with 555-
569 loop of A2-domain [51]. Taken the data together, it
becomes apparent from the current zymogen model that
the activation peptide loop between the A1 and A2
domains blocks the complex formation between fVIII
and fIXa. Based on MD simulations on fVIIIa, in which
the Arg372-Ser373 bond gets cleaved, our model of
fVIIIa predicts that the cleaved peptide linker between
A1 and A2 domains undergoes significant conforma-
tional changes upon activation. Indeed the peptide seg-
ment Pro330-Arg372, in the activated form, completely
restructures and relocates to the A1-domain (Figure 3).
This conformational reorganization leads to full expo-
s u r eo ft h ep u t a t i v ef I X ab i n d i n gs i t ew i t h i nt h e
A2-domain for productive complex formation between
the fIXa enzyme and fVIIIa co-factor. We must empha-
size that the proposed linker peptide between the A1
and A2 domains is truly predictive in nature, albeit
s h e d ss o m el i g h to nt h el i k e l yc o n f o r m a t i o nt h a tt h e
peptide linker might adopt. Whether the proposed con-
formation for the linker structure is indeed true or not
can only be attested by experimental validation. Consid-
ering that we were able to reproduce the helical nature
for the 9 residue long acidic patch and the short peptide
preceding the proteolytic site may instill some confi-
dence in the proposed structure.
Conclusions
In the present study, we applied a step-wise modeling
and MD refinement approach to develop the solution
structural models of the zymogenic and activated forms
of B-domainless human factor VIII based on the X-ray
crystal structure of human fVIII. The models showed
significant improvement in the stereochemical quality of
the core region of the domains over the X-ray crystal
structure. The solvent equilibrated models derived from
several hundred nanoseconds of MD simulations in
explicit water provided a detailed understanding of the
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defects in fVIII lead to the hereditary bleeding disorder,
Hemophilia-A. More than 200 natural mutations are
known that cause mild to severe bleeding in hemophilia
patients. While a detailed structure-function correlation
of the known genetic and synthetic mutations with
fVIII/fVIIIa structures is beyond the scope of the pre-
sent work, we were able to successfully correlate some
of the recently reported experimental mutagenesis data
with the MD derived models.
In the absence of experimental structural data, we
applied MD simulation techniques to predict the likely
conformations for the linker peptides between the A1:
A2 and A2:A3 domains. Though the models are derived
from long time scale MD simulations and appear to be
well-stabilized during the dynamics, we must emphasize
that the loop conformations are truly predictive in nat-
ure and need experimental attestation. However the pro-
posed model for the linker peptide between A1 and A2
domains may shed some light on the current under-
standing of the zymogenicity of fVIII. The linker peptide
between A1 and A2 domains was predicted to block the
“steric access” of the putative factor IXa binding region
(Tyr555-Asp569) in the A2-domain. The simulation of
the activated form predicted that the loop re-organizes
upon cleavage and relocates to A1 domain, thereby
exposing the Tyr555-Asp569 loop and the surrounding
region. Since this loop was proposed by several experi-
mental studies as functionally important for fIXa
enzyme binding, the conformational differences between
fVIII and fVIIIa in the current study may provide a
structural basis for the zymogenecity of fVIII and the
importance of the proteolysis of Arg372-Ser373 peptide
bond for productive interactions between fIXa and
fVIIIa. The extensive MD simulations employed in the
current study also characterize the specific residues
involved in the co-ordination network of the high-affi-
nity calcium-ion within the A1-domain. The proposed
data related to the inter-domain interactions may serve
as a reasonable structural basis to design the site-speci-
fic mutagenesis studies to further characterize the resi-
dues involved in promoting the overall stability of fVIII/
fVIIIa and, in turn, the validation of the proposed solu-
tion structures.
Methods
Upon the loss of a 19 residue length signal peptide, the
mature fVIII zymogen circulates in blood as a single
chain protein with 2332 residues (A1-A2-B-A3-C1-C2)
out of which the B-domain consists of 573-residues [52].
Factor VIII was experimentally characterized to possess
eight disulfide bonds [53]. Each of the A-domains con-
tains two disulfide bonds and one free cysteine residue
while the C1 and C2 domains possess one disulfide
bond in each domain. The function of fVIII has long
been implicated to depend critically on the binding of
calcium and copper ions to the protein [29,54-57]. Sev-
eral biochemical studies proposed that the A1 domain
contains one high-affinity calcium ion while there might
be a low-affinity calcium ion bound to the other A-
domains, though the specific details were not known
[58,59]. Also, the binding of a Type-I copper ion in each
of the A1 and A3 domains and a Type-II copper ion
binding at the interface of A1 and A3 domains were
proposed based on comparison with copper ion binding
network in several copper-binding proteins as well as
experimental mutagenesis studies [60].
The B-domain in fVIII has no known structural
homology in the protein database. Consequently, the
modeling of B-domain is intractable to modern compu-
tational methods. The single-chain fVIII protein without
the B-domain (741-1668) appeared to retain the full
fVIII functionality as investigated by Donath et al [61].
In their study, the A1-A2 domains (Ala1-Arg740) were
directly fused with A3-C1-C2 domains (Ser1669-
Tyr2332) to generate a single-chain B-domainless fVIII
protein. The fusion site, Arg740-Ser1669, was proposed
to be functionally similar to other cleavage sites and was
readily cleaved by thrombin and fXa. Thus, the exclu-
sion of B-domain of zymogen fVIII may be considered
to bear no effect on the structure-function studies
related to fVIII protein and its activation pathways. The
lack of experimental structural data for the missing lin-
ker peptides between A1:A1 and A2:A3 poses a major
challenge to computational modeling as the peptide
sequences are 40-50 residue long. In this study, we
applied a step-wise modeling approach to generate the
full models of fVIII and fVIIIa in several stages as
described below.
Step1. Refinement of the core structure of fVIII zymogen
The full model of single chain B-domainless fVIII was
generated using the 3.7 Å resolution X-ray structure of
the fVIII zymogen (PDB:2R7E) [13]. The crystal struc-
tural coordinates for the B-domainless protein reported
include: Ala1-Asn214; Ala222-Gln334; Phe360:Asp725;
Arg1689-Tyr2332. We modeled the missing loop resi-
dues between Asn214 and Ala222 using the MODLOOP
server http://modbase.compbio.ucsf.edu/modloop/mod-
loop.html[62]. The initial X-ray crystal structure was
processed to include one calcium ion in the A1-domain
and one copper (I) ion each in the A1 and A3 domains.
The coordinates for the ions corresponded to those in
the crystal structure. The calcium ion in the crystal
structure was not well positioned as it was found to
coordinate with only two atoms. These atoms corre-
spond to one of the side-chain carboxylate atoms of
Asp126 and the backbone oxygen atom of Ala110 within
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the acidic-rich calcium binding loop were positioned at
least 5 Å away from the calcium ion. The copper (I)
ions within the A1 and A3-domain were located within
the coordinating distance of His1954/Cys2000/His2005/
Met2010 and His267/Cys310/Met320/His315. In addi-
tion, we introduced one copper (II) ion at the A1-A3
domain interface with the coordinating residues His99/
His161 of A1- domain and His1957 of A3-domain, in
consensus with the reported experimental studies as
well as the structural comparison with other copper-
binding proteins [29,63-66]. The starting model used for
MD refinement contained the following residues: A1
(Ala1-Gln334); A2 (Lys376-Thr715); A3-C1-C2
(Arg1689-Tyr2332). The crystal structure together with
the copper and calcium ions was immersed in a period
box of waters to set up the MD simulation. The model
was subjected to initial refinement of 15 ns of MD
simulations in explicit water medium in order to relax
the structure and to improve the overall stereochemical
space of the structure. Analysis of the structure corre-
sponds to the 15 ns of MD trajectory showed ~7 Å
RMS deviation from the starting structure when super-
imposed the backbone atoms of the two structures. The
resulting structure was subsequently used to model the
missing linker peptides connecting the A1/A2 and A2/
A3 domains as described below.
Step2: Generation of acidic linker structure between
A1 and A2 domains
The 46-residue length linker peptide between Glu332
and Pro379 is predominantly acidic with 18 residues
being negatively charged. The sequence from 341 to 349
(EEAEDY*DDD) has large density of acidic residues.
The residue Tyr346 (Y*) in the sequence represents sul-
fated tyrosine. Attempts to generate a possible structure
for the linker peptide using homology modeling meth-
ods failed due to no corresponding template structure in
the PDB. Consequently, the structure of the peptide was
modeled using MD simulations for a total time period
of more than 200 ns. Initially two beta-sheets that con-
nect the linker peptide from the core residues of A1
(Ala322-Glu332) and A2 domain (Pro379-Ala388) were
selected from the solvent equilibrated model (step1) as
shown in Figure 7a. Analysis of the structure showed
that the distance of backbone Ca atoms between
Glu332 and Pro379 residues was 30.4 Å. A possible
structure for the missing linker peptide between two
connecting residues was generated by starting from a
linear conformation for the sequence Glu332-Pro379. In
order to let the structure fold into stable conformation,
the structure was subjected initially to a 100 ns of
unconstrained MD simulations in explicit water. Then,
while imposing distance constraint of 30 Å between the
two Ca atoms of Glu332 and Pro379, the structure was
further simulated for additional 50 ns. The resulting lin-
ker peptide structure was then superimposed manually
with the coordinates of the two beta sheet structures
such that Glu332 and Lys377 residues form peptide
bonds with Pro333 and His378 respectively. The confor-
mation of the peptide bonds Glu332-Pro333 and
Lys377-His378 were adjusted to acceptable Phi-Psi
values. While constraining the residues Ala322-Cys329
of A1-domain and Thr381-Ala388 of A2-domain, the
resulting model was subjected to 100 ns of MD simula-
tions in explicit water. These residues were constrained
in order to be able to insert, subsequently, the optimized
loop structure back into the model of fVIII from step1.
The last 30 ns of the stabilized MD trajectories were
clustered to generate 10 possible conformations for the
linker peptide as shown in Figure 7b. All conformations
were superimposed against the MD equilibrated model
of fVIII from step1. Since the two beta-sheets of A1 and
A2 domains were constrained during the optimization
o ft h el i n k e rp e p t i d e ,w ew e r ea b l et oa l i g nt h ec o o r d i -
nates of the beta-sheets with the corresponding residues
in the MD equilibrated model (from step1). Out of the
ten structures, only two conformations satisfied the spa-
tial constraints such that the peptide could be inserted,
with no steric clashes, into the model of fVIII. The rest
of the structures did not fit into the fVIII structure as
they overlapped with the core residues of A1 and A2
domains. We chose one of the two conformations to fit
between the A1 and A2 domains to complete the miss-
ing linker peptide.
Step3: Generation of linker peptide structure between
A2 and A3 domains
The structure prediction for the linker peptide between
the A2 and A3 domains followed a similar approach
adopted in step2. MD simulations on fVIII model from
step1 revealed that the C-terminal residues from 712 to
725 within the A2-domain appear to be flexible with no
stabilization of the conformation. Consequently, these
residues were deleted from the model of fVIII and
reconstructed to build the linker peptide between
Cys711 and Arg1689. The linker peptide from Cys711
to Arg740 of A2-domain and Ser1669-Arg1689 forms a
contiguous sequence in the B-domainless fVIII model
considered in the present study. The Ca-Ca distance
between Cys711 (A2-domain) and Ser1690 (A3-domain)
in the solvent equilibrated model of fVIII (from step1) is
~43 Å. In order to generate a possible structure for
the linker peptide using MD simulations, a short
model of A2 and A3 domains was selected from the
MD equilibrated model of fVIII (from step1). The
model comprised of selected residues of the A2 and A3
domains. The residues corresponded to: Val621-Ile639/
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Ser1690-Arg1705/Gly1760-Pro1809/Glu1811-Lys1827 of
A3-domain. We chose the reduced model in place of
the full structure of fVIII to increase the computational
speed of MD simulations and also to minimize the com-
putational cost. Initially, a random conformation was
created for the missing linker peptide corresponding to
the residues between Asp712-Arg740 and Ser1669-
Ser1690 as a contiguous sequence (Figure 8a). The
Arg740 (A2-domain)-Ser1669 (A3-domain) residues
were directly bonded to represent the contiguous
B-domainless fVIII structure. The tyrosine residues at
positions 718, 719 and 723 were post-translationally
modified in fVIII. Accordingly, the side-chain hydroxyl
group in the three residues was modified to include the
sulfated group. The positional constraints were applied
during the simulation such that only the linker peptide
region (Asp712-Arg740-Ser1669-Ser1690) moved while
the rest of the protein remains constrained. The model
was subsequently refined for 100 ns of MD simulation
to generate a possible conformation for the linker
peptide.
Step4: Full model of B-domainless Factor VIII zymogen
The solvent-equilibrated models of A1-A2 and A2-A3
linker peptide structures, derived from the steps 2 and 3,
were inserted into the equilibrated model from step-1 to
generate the full structure of fVIII. Since the non-loop
regions of the models used for A1-A2 and A2-A3 linker
peptide modeling were constrained during the MD
simulations, both models superimposed with the solvent
equilibrated model (step1) with no steric clashes.
Sequence characterization studies showed that asparagine
(ASN) residues at positions 41, 239, 582, 1810 and 2118
were post-translational glycosylation sites [67]. Accord-
ingly, these sites were modified to include the N-linked
acetyl glucosamine (N-GlcNAc) carbohydrate attach-
ments using the GLYCAM server http://glycam.ccrc.uga.
edu/. In addition, tyrosine (TYR) residues at positions
346 (within the A1-A2 linker region) was modified to
incorporate the sulfated tyrosines [38]. The other three
tyrosine sulfation sites at 718, 719 and 723 positions at
the C-terminus of A2-domain were already modified in
the step3. The final model was subsequently refined for
70 ns of MD simulations in explicit water medium.
Step5: Full model of activated Factor VIII
The domain organization of fVIII zymogen and its acti-
vated form, fVIIIa, are similar except that the activated
form does not possess B-domain. The residues involved
in the inter-domain interactions between A1:A2 and A2:
A3 domains appeared to be comparable as suggested by
recent site-specific mutagenesis studies [6,68,69]. In this
study, a panel of 30 residues that appeared to be impor-
tant for A1:A2 and A2:A3 interactions were subjected to
alanine mutagenesis in both fVIII and fVIIIa. The
reported protein decay rates in most of the mutants
were comparable in both active and zymogen forms,
suggesting that the residues involved in the inter-
domain interactions might be identical. Thus, it may be
reasonable to model the activated form from the zymo-
genic structure.
In order to build the activated fVIII model in which
the Arg372-Ser373 peptide bond gets cleaved during the
proteolysis by thrombin and/or Xa, the solvent-equili-
brated fVIII zymogen structure, derived from the 70 ns
of MD simulations, was modified to generate the acti-
vated form. This was accompl i s h e db ye x p l i c i t l yb r e a k -
ing the Arg372 and Ser373 bond and creating a hetero-
trimeric complex among the A1 (Ala1-Arg372), A2
(Ser373-Arg740) and A3-C1-C2 (Ser1690-Tyr2332)
domains. The full model of fVIIIa, thus obtained, was
subjected to further refinement of 75 ns of MD simula-
tions to obtain the solution structure of fVIIIa.
MD simulations details
The MD simulations on all the structures, considered in
the present study, were carried out in explicit water med-
ium using AMBER10 program (Scripps Research Insti-
tute, San Deigo, CA) package with PARM99/SB force-
field [70,71]. The force-field parameters for the copper
ion were adopted from the earlier work [72]. The charge
parameters for the sulfated tyrosine were derived by
RESP-fit method on a model of Tyrosine sulfate using
HF/6-31G* basis set to be consistent with PARM99
force-field parameters. The corresponding charges are:
OG (-0.4318); S (1.2426); O1S (-0.64); O2S (-0.64); O3S
(-0.64). The rest of the tyrosine residue charges were
constrained during the charge fitting scheme.
The long-range interactions were treated using the
particle mesh Ewald (PME) method [73]. Constant tem-
perature and pressure (300 K/L.atm) were maintained
throughout the simulations using the Berendsen scaling
algorithm with coupling constant of 0.2 ps [74]. All
bonds involving hydrogen atoms were constrained using
the SHAKE algorithm. A time step of 2 fs was used to
integrate the equations of motion. Before beginning the
production-run simulations, the following equilibration
protocol was followed.
1) The water molecules and counter-ions in the per-
iodic box were energy minimized to a root mean
square (RMS) gradient of 0.1 kcal/mol/A
2.T h i sf o l -
lowed a full minimization of the entire system.
2) NVT simulation for 5 ps was performed on the
entire system.
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whole system except the backbone atoms of the pro-
tein residues to equilibrate the solvent waters and
the protein side-chain atoms.
4) The entire system is subjected to slow heat-up
from the initial temperature of 150 K to 300 K
under NVT conditions.
5) Finally the system was subjected to production-
run under NPT conditions and a constant tempera-
ture of 300 K. The final density of all the simulations
in the current study was close to 0.99 g/cc.
Analysis and clustering of the MD trajectories were
performed using the ptraj module of AMBER10 pack-
age. The simulations of full length structures of fVIII
and fVIIIa were performed without any geometrical or
positional constraints on the atoms. The computations
were performed on the multi-core linux clusters using
MPI/Infiniband version of PMEMD. The final setup of
the zymogen and the activated forms of fVIII for MD
simulations is given below.
a) Factor VIII: Total system size: 242,051 atoms; 1404
protein residues; 7 calcium ions (6 unbound to protein);
1 chloride ion; 73158 waters
b) Factor VIIIa: Total system size: 202,946 atoms;
1383 protein residues; 5 calcium ions (4 unbound to
protein); 1 chloride ion; 60235 waters
Structural coordinates information
T h ea t o m i cc o o r d i n a t e so ft h es o l v e n t - e q u i l i b r a t e d
structures of fVIII and fVIIIa are deposited at protein
model database http://mi.caspur.it/PMDB/main.php.
The accession numbers for PDB coordinates is
PM0076106 and PM0076119.
Additional file 1: Figure S1. The Phi-Psi Ramachandran plots (only non-
glycine residues were considered) of the X-ray crystal (upper left), initial
homology model (upper right), the solvent-equilibrated MD models of
fVIII zymogen (lower left) and activated form (lower right).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-6807-10-7-
S1.DOC]
Additional file 2: Figure S2. Overlay of the MD equilibrated structure of
fVIII zymogen (white) and the X-ray crystal structure (PDB:2R7E). The
backbone atoms of the individual domains of A1, A2, A3, C1 and C2 of
the X-ray crystal structures (color-coded) were superimposed against the
MD model.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-6807-10-7-
S2.DOC]
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